Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes

Summary Developments in basic stem cell biology have paved the way for technology translation in human medicine. An exciting prospective use of stem cells is the ex vivo generation of hepatic and pancreatic endocrine cells for biomedical applications. This includes creating novel models ‘in a dish’ and developing therapeutic strategies for complex diseases, such as metabolic dysfunction‐associated steatotic liver disease (MASLD) and diabetes. In this review, we explore recent advances in the generation of stem cell‐derived hepatocyte‐like cells and insulin‐producing β‐like cells. We cover the different differentiation strategies, new discoveries, and the caveats that still exist regarding their routine use. Finally, we discuss the challenges and limitations of stem cell‐derived therapies as a clinical strategy to manage metabolic diseases in humans.